Cidara Theraptcs Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cidara Theraptcs has an operating margin of -13811.9%, meaning the company retains $-13812 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -116.2% the prior year.
Cidara Theraptcs's revenue declined 94.5% year-over-year, from $23.3M to $1.3M. This contraction results in a growth score of 0/100.
Cidara Theraptcs carries a low D/E ratio of 0.32, meaning only $0.32 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.25, Cidara Theraptcs holds $4.25 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Cidara Theraptcs generated -$176.5M in operating cash flow, capex of $129K consumed most of it, leaving -$176.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Cidara Theraptcs passes 1 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Cidara Theraptcs generates $1.04 in operating cash flow (-$176.5M OCF vs -$169.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Cidara Theraptcs (CDTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Cidara Theraptcs generated $1.3M in revenue in fiscal year 2024. This represents a decrease of 94.5% from the prior year.
Cidara Theraptcs's EBITDA was -$175.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 552.9% from the prior year.
Cidara Theraptcs generated -$176.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 670.2% from the prior year.
Cidara Theraptcs reported -$169.8M in net income in fiscal year 2024. This represents a decrease of 640.6% from the prior year.
Cidara Theraptcs earned $-26.75 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 409.5% from the prior year.
Cidara Theraptcs held $189.8M in cash against $0 in long-term debt as of fiscal year 2024.
Cidara Theraptcs had 11M shares outstanding in fiscal year 2024. This represents an increase of 141.6% from the prior year.
Cidara Theraptcs's operating margin was -13811.9% in fiscal year 2024, reflecting core business profitability. This is down 13695.7 percentage points from the prior year.
Cidara Theraptcs's net profit margin was -13319.8% in fiscal year 2024, showing the share of revenue converted to profit. This is down 13221.3 percentage points from the prior year.
Cidara Theraptcs invested $71.9M in research and development in fiscal year 2024. This represents an increase of 95.5% from the prior year.
Cidara Theraptcs invested $129K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 74.5% from the prior year.
CDTX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0-100.0% | $302K-89.3% | $2.8M | N/A | $9.2M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $35.5M+43.2% | $24.8M+0.9% | $24.6M+97.9% | $12.4M+86.7% | $6.7M+12.5% | $5.9M | N/A | $10.4M |
| SG&A Expenses | $8.1M+24.6% | $6.5M+5.2% | $6.2M+24.5% | $5.0M+4.6% | $4.7M+32.0% | $3.6M | N/A | $3.3M |
| Operating Income | -$88.6M-223.6% | -$27.4M-8.4% | -$25.3M-45.3% | -$17.4M+81.9% | -$96.0M-1023.7% | -$8.5M | N/A | -$4.5M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | N/A | -$32K |
| Net Income | -$83.2M-223.6% | -$25.7M-9.5% | -$23.5M-46.9% | -$16.0M+82.5% | -$91.2M-783.3% | -$10.3M | N/A | -$9.1M |
| EPS (Diluted) | $-3.10-87.9% | $-1.65+0.6% | $-1.66+32.2% | $-2.45+87.7% | $-19.99-776.8% | $-2.28 | N/A | $-2.02 |
CDTX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $518.6M-2.9% | $534.3M+178.7% | $191.7M-10.7% | $214.8M+23.9% | $173.4M+228.9% | $52.7M-21.4% | $67.0M+4.5% | $64.1M |
| Current Assets | $442.8M-16.7% | $531.8M+181.6% | $188.8M-10.4% | $210.7M+25.0% | $168.6M+260.0% | $46.8M-23.0% | $60.9M+4.1% | $58.5M |
| Cash & Equivalents | $293.7M-42.5% | $510.6M+203.6% | $168.2M-11.4% | $189.8M+15.5% | $164.4M+466.4% | $29.0M-18.9% | $35.8M-26.5% | $48.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | $7.3M+19.2% | $6.1M+110.2% | $2.9M |
| Accounts Receivable | $1.9M+0.1% | $1.9M+9.7% | $1.7M0.0% | $1.7M-27.9% | $2.3M-67.7% | $7.3M-48.3% | $14.1M+342.9% | $3.2M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $96.3M+190.4% | $33.2M-33.8% | $50.0M-2.8% | $51.5M+21.4% | $42.4M-39.8% | $70.5M-6.3% | $75.2M+7.4% | $70.0M |
| Current Liabilities | $95.8M+196.5% | $32.3M-33.8% | $48.8M-1.5% | $49.6M+25.0% | $39.6M-39.4% | $65.4M-3.0% | $67.4M+34.2% | $50.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $422.4M-15.7% | $501.2M+253.7% | $141.7M-13.2% | $163.3M+24.7% | $130.9M+836.4% | -$17.8M-116.6% | -$8.2M-39.3% | -$5.9M |
| Retained Earnings | -$743.7M-12.6% | -$660.5M-4.1% | -$634.7M-3.8% | -$611.3M-12.6% | -$543.0M-20.2% | -$451.8M-2.3% | -$441.4M-0.7% | -$438.2M |
CDTX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.6M+0.8% | -$41.0M-86.6% | -$21.9M+25.4% | -$29.4M+71.7% | -$103.8M-1462.0% | -$6.6M+47.8% | -$12.7M-678.6% | -$1.6M |
| Capital Expenditures | $0 | $0 | $0 | $0 | $0-100.0% | $23K-87.1% | $178K+41.3% | $126K |
| Free Cash Flow | -$40.6M+0.8% | -$41.0M-86.6% | -$21.9M+25.4% | -$29.4M+71.7% | -$103.8M-1456.6% | -$6.7M+48.3% | -$12.9M-633.0% | -$1.8M |
| Investing Cash Flow | -$176.5M | $0-100.0% | $185K | $0 | $0+100.0% | -$23K+87.1% | -$178K-41.3% | -$126K |
| Financing Cash Flow | $160K-100.0% | $383.4M+497802.6% | $77K-99.9% | $98.2M-58.9% | $239.1M+257230.1% | -$93K-1262.5% | $8K | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CDTX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | -31782.8%-31480.5pp | -302.3% | N/A | -48.5% |
| Net Margin | N/A | N/A | N/A | N/A | -30201.7%-29836.3pp | -365.4% | N/A | -98.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -16.1%-11.2pp | -4.8%+7.4pp | -12.3%-2.4pp | -9.8%+42.8pp | -52.6%-33.0pp | -19.6% | N/A | -14.2% |
| Current Ratio | 4.62-11.8 | 16.45+12.6 | 3.87-0.4 | 4.250.0 | 4.25+3.5 | 0.72-0.2 | 0.90-0.3 | 1.16 |
| Debt-to-Equity | 0.23+0.2 | 0.07-0.3 | 0.35+0.0 | 0.320.0 | 0.32+4.3 | -3.96+5.2 | -9.16+2.7 | -11.88 |
| FCF Margin | N/A | N/A | N/A | N/A | -34364.2%-34128.3pp | -235.9% | N/A | -19.1% |
Similar Companies
Frequently Asked Questions
What is Cidara Theraptcs's annual revenue?
Cidara Theraptcs (CDTX) reported $1.3M in total revenue for fiscal year 2024. This represents a -94.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cidara Theraptcs's revenue growing?
Cidara Theraptcs (CDTX) revenue declined by 94.5% year-over-year, from $23.3M to $1.3M in fiscal year 2024.
Is Cidara Theraptcs profitable?
No, Cidara Theraptcs (CDTX) reported a net income of -$169.8M in fiscal year 2024, with a net profit margin of -13319.8%.
What is Cidara Theraptcs's earnings per share (EPS)?
Cidara Theraptcs (CDTX) reported diluted earnings per share of $-26.75 for fiscal year 2024. This represents a -409.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Cidara Theraptcs's EBITDA?
Cidara Theraptcs (CDTX) had EBITDA of -$175.9M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cidara Theraptcs's operating margin?
Cidara Theraptcs (CDTX) had an operating margin of -13811.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Cidara Theraptcs's net profit margin?
Cidara Theraptcs (CDTX) had a net profit margin of -13319.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Cidara Theraptcs's free cash flow?
Cidara Theraptcs (CDTX) generated -$176.7M in free cash flow during fiscal year 2024. This represents a -670.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cidara Theraptcs's operating cash flow?
Cidara Theraptcs (CDTX) generated -$176.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Cidara Theraptcs's total assets?
Cidara Theraptcs (CDTX) had $214.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Cidara Theraptcs's capital expenditures?
Cidara Theraptcs (CDTX) invested $129K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Cidara Theraptcs spend on research and development?
Cidara Theraptcs (CDTX) invested $71.9M in research and development during fiscal year 2024.
How many shares does Cidara Theraptcs have outstanding?
Cidara Theraptcs (CDTX) had 11M shares outstanding as of fiscal year 2024.
What is Cidara Theraptcs's current ratio?
Cidara Theraptcs (CDTX) had a current ratio of 4.25 as of fiscal year 2024, which is generally considered healthy.
What is Cidara Theraptcs's debt-to-equity ratio?
Cidara Theraptcs (CDTX) had a debt-to-equity ratio of 0.32 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cidara Theraptcs's return on assets (ROA)?
Cidara Theraptcs (CDTX) had a return on assets of -79.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Cidara Theraptcs's cash runway?
Based on fiscal year 2024 data, Cidara Theraptcs (CDTX) had $189.8M in cash against an annual operating cash burn of $176.5M. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cidara Theraptcs's Piotroski F-Score?
Cidara Theraptcs (CDTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cidara Theraptcs's earnings high quality?
Cidara Theraptcs (CDTX) has an earnings quality ratio of 1.04x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Cidara Theraptcs?
Cidara Theraptcs (CDTX) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.